## **Myeloproliferative Neoplasms (MPNs) Panels**

- I. Myeloproliferative neoplasm (MPN) molecular profiling panels are considered **medically necessary** when:
  - A. The member is suspected to have a myeloproliferative neoplasm (MPN), **AND**
  - B. The panel includes, at a minimum, testing of the following genes: *JAK2*, *CALR*, and *MPL*.
- II. Myeloproliferative neoplasm (MPN) molecular profiling panels are considered **investigational** for all other indications.

## DEFINITIONS

- 1. A **Myeloproliferative Neoplasm (MPN)** is a rare blood disease in which the bone marrow makes too many red blood cells, white blood cells, or platelets. There are seven subcategories of myeloproliferative neoplasms:
  - a. Chronic myeloid leukemia (CML)
  - b. Polycythemia vera (PV)
  - c. Primary myelofibrosis (PMF)
  - d. Essential thrombocytopenia (ET)
  - e. Chronic neutrophilic leukemia
  - f. Chronic eosinophilic leukemia
  - g. Chronic eosinophilic leukemia-not otherwise specified
  - h. MPN, unclassifiable (MPN-U)



Oncology Testing: Hematologic Malignancy Molecular Diagnostics 2025.2

Effective: 07/01/2025 Last Revision: 02/20/2025 Last Clinical Review: 01/31/2025

## REFERENCES

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. Version 2.2024 https://www.nccn.org/professionals/physician\_gls/pdf/mpn.pdf

